[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-lesion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-lesion":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,76,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100511096","contribution-of-multiparametric-analysis-in-bone-scintigraphy-for-the-characterisation-of-solitary-bone-lesions-100511096",false,"NCT05934994","Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions","Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions Whose Malignant Origin Cannot be Excluded on Conventional Imaging","MUSIC","Inclusion Criteria:\n\n* Person, having received complete information on the organization of the research and having signed the informed consent and:\n\n  * Age ≥ 18 years old.\n  * Having read and understood the information document.\n  * Affiliated to a social security scheme.\n* Patient with an indeterminate solitary bone lesion on conventional imaging, for which an indication for biopsy +\u002F- excision is planned.\n\nExclusion Criteria:\n\n* Pregnant woman or woman of childbearing age and without contraceptive means or nursing mother.\n* Unstable medical condition and\u002For inability to remain still during recordings.\n* Known allergy to one of the components of the radiopharmaceutical technetium-99m-Technescan HDP (product required to perform the bone scan).\n* Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code.\n* Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1, L. 3213-1","ALL","18 Years","90 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25],"NA","The hypothesis of the study is that non-invasive Single photon emission computed tomography (SPECT-CT) bone scintigraphy makes it possible to better characterize solitary bone lesions, in particular the exclusion of their malignancy in order to avoid unnecessary biopsy and possible complications for the patient.",[28],"Bone Lesion","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2023-09-11",{"date":37,"type":22},"2027-01-10",{"name":39,"class":40},"Central Hospital, Nancy, France","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100574042","assessing-ai-supported-fracture-detection-in-emergency-care-units-100574042","NCT06754137","Assessing AI-Supported Fracture Detection in Emergency Care Units","Evaluating the Cost-Efficiency and Workflow Impact of AI-Supported Fracture Detection in an Orthopedic Emergency Care Unit","Inclusion Criteria:\n\n* Presenting to the emergency department with an isolated injury or joint complaint\n* Patients able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with injuries or complaints involving multiple body regions\n* Patients with prior imaging of the affected extremity or region within the past 6 months\n* Contraindications to X-ray imaging (e.g., pregnancy or severe instability)\n* Patients with other ongoing studies that may interfere with this study\n* Patients unable to provide consent due to cognitive impairment or language barriers without an available representative.",{"count":50,"type":22},4800,[25],"Brief Summary The purpose of this study is to determine if artificial intelligence (AI) can assist doctors in detecting broken bones, effusions, dislocations and bone lesions more quickly and accurately in an emergency room setting. The study will also evaluate whether AI can save time and reduce costs in healthcare.\n\nThe main questions to be addressed are:\n\n* Does AI improve the accuracy of detecting broken bones\u002Fdislocations\u002Feffusions\u002Fbone lesions?\n* Can AI expedite the process of diagnosing broken bones\u002Fdislocations\u002Feffusions\u002Fbone lesions?\n* Does AI reduce healthcare costs by enhancing efficiency?\n\nTo investigate these questions, two groups of patients will be compared. One group will follow the traditional diagnostic approach, while the other group will utilize AI to assist in diagnosing X-rays.\n\nParticipants in the study will:\n\nUndergo standard X-ray imaging of injured arms or legs, as part of routine care.\n\nHave X-rays reviewed by doctors with or without AI support, depending on the assigned group.\n\nThe study will include patients of all ages presenting to the emergency room with an isolated injury or joint complaints. No additional tests or treatments beyond standard care will be involved.",[54,55,28,56],"Fractures, Bone","Effusion Joint","Dislocation",[58,59,60,61,62,63,64,65,56,28],"Artificial Intelligence","Fracture Detection","Emergency Care","Cost-Efficiency","AI-Assisted Diagnosis","Diagnostic Accuracy","Orthopedic Diagnostics","Effusion","2026-01-20",{"date":68,"type":33},"2026-01-22",{"date":70,"type":33},"2025-03-31",{"date":72,"type":22},"2026-04-30",{"name":74,"class":40},"Salzburger Landeskliniken",3,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100601724","a-study-on-the-diagnostic-value-of-99mtc-fapi-quantitative-spectct-imaging-in-adult-solitary-bone-lesions-100601724","NCT07114211","A Study on the Diagnostic Value of 99mTc-FAPI Quantitative SPECT\u002FCT Imaging in Adult Solitary Bone Lesions","A Real-world Observational Study on the Diagnostic Value of 99mTc-FAPI Quantitative SPECT\u002FCT Imaging in Adult Solitary Bone Lesions","Inclusion Criteria:\n\n* Benign solitary bone lesions in adults (fibrous cortical defects, fibrous hyperplasia, non-ossifying fibroma, osteoblastoma, osteoid osteoma, osteochondroma, etc.); Malignant solitary bone lesions in adults (osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant giant cell tumour of bone, etc.); Other fibroblast-rich bone lesions (chordoma, alveolar soft part sarcoma, fibrosarcoma, malignant fibrous histiocytoma, etc.).\n\nExclusion Criteria:\n\n* Severe liver and kidney dysfunction; Pregnant women and breastfeeding patients; Patients in poor physical condition who cannot tolerate the examination; Patients who cannot cooperate to complete the examination; Patients under the age of 18.","80 Years",{"count":85,"type":22},50,[25],"Using the novel FAPI probe 99mTc-HYNIC-FAPI-04 and quantitative SPECT\u002FCT imaging technology, this study investigates the diagnostic efficacy of 99mTc-HYNIC-FAPI-04 quantitative SPECT\u002FCT in patients with common solitary bone lesions in adults, and compares its diagnostic performance with conventional CT, MRI, and 99mTc-MDP bone scintigraphy. Follow-up pathological results of patients post-surgery were analysed to assess the accuracy of 99mTc-HYNIC-FAPI-04 diagnostic outcomes, and its diagnostic value and significance were evaluated.",[28,89],"SPECT-CT","NOT_YET_RECRUITING","2025-08-04",{"date":93,"type":33},"2025-08-11",{"date":95,"type":22},"2025-08-15",{"date":97,"type":22},"2028-06-01",{"name":99,"class":40},"Xijing Hospital",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100535290","efficacy-of-bioceramic-materials-for-bone-defects-repair-100535290","NCT06249906","Efficacy of Bioceramic Materials for Bone Defects Repair","Clinical Study of Bioceramic Materials in Bone Defect Repair","Inclusion Criteria:\n\n1. Patients who voluntarily take the test and sign the informed consent form;\n2. Patients aged 18-65 years old with no history of allergies;\n3. Patients able to communicate well with the investigator and follow the requirements of the entire trial.\n\nExclusion Criteria:\n\n1. Patients who refuse to sign the informed consent form to participate in the trial;\n2. Patients who are not in the age range of 18 to 65 years;\n3. Patients with diseases unsuitbale for the trial: history of allergies, severe cardiopulmonary disease, coagulation dysfunction, Alzheimer's disease, cerebral atrophy, acute phase or sequelae of cerebrovascular disease, cognitive impairment;\n4. Patients in the acute phase of local or systemic bacterial infections;\n5. Patients who cannot cooperate with the operation and evaluate the effect;\n6. Other conditions that are considered inappropriate by the investigator to participate in the study.","65 Years",{"count":109,"type":22},10,[25],"The purpose of this study is to demonstrate the effect of bioceramic implants on the repair of human bone defects, and to explore the application of bioceramic materials in bone defects, bone implantation, and bone fusion. The surface microstructure of β-tricalcium phosphate bioceramic implants can be effectively controlled to guide the regeneration of bones, promote the restoration of bones, accelerate the speed of recovery, and improve bone quality, which is of great clinical and social significance.",[28,113,114,115,116,117],"Cartilage Degeneration","Osteo Arthritis Knee","Bone Fracture","Bone Injury","Bone Loss","2024-03-08",{"date":120,"type":33},"2024-03-12",{"date":122,"type":33},"2024-02-20",{"date":124,"type":22},"2026-12-30",{"name":126,"class":40},"Nanjing First Hospital, Nanjing Medical University"]